Results 11 to 20 of about 22,013 (249)

The pathogenic c.1171A>G (p.Arg391Gly) and c.2359G>A (p.Val787Ile) ABCC6 variants display incomplete penetrance causing pseudoxanthoma elasticum in a subset of individuals

open access: yesHuman Mutation, Volume 43, Issue 12, Page 1872-1881, December 2022., 2022
Abstract ABCC6 promotes ATP efflux from hepatocytes to bloodstream. ATP is metabolized to pyrophosphate, an inhibitor of ectopic calcification. Pathogenic variants of ABCC6 cause pseudoxanthoma elasticum, a highly variable recessive ectopic calcification disorder.
Flora Szeri   +15 more
wiley   +1 more source

Neurological autoimmune diseases following vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2): A follow‐up study

open access: yesEuropean Journal of Neurology, Volume 30, Issue 2, Page 463-473, February 2023., 2023
In this study we define long‐term characteristics of various neurological autoimmune disorders encountered after SARS‐CoV‐2 vaccinations. Long‐term outcome was favorable in most cases. Re‐vaccinations were well‐tolerated and should be considered on an individual risk/benefit analysis.
Sofia Doubrovinskaia   +11 more
wiley   +1 more source

Intermittent claudication [PDF]

open access: yesCurrent Treatment Options in Cardiovascular Medicine, 2001
Intermittent claudication is the most common symptom in patients with peripheral arterial disease (PAD). As such, it is mandatory for clinicians to treat both the PAD-specific symptoms (to decrease functional impairment and thereby improve quality- of-life, as well as to decrease rates of amputation) and the underlying systemic atherosclerosis (and ...
Alan T., Hirsch, Laura, M Reich
openaire   +2 more sources

Assessment of Walking Ability in Patients with Intermittent Claudication Using a Smartphone Accelerometer

open access: yesJournal of Scientific Innovation in Medicine, 2021
Objectives: It is challenging to accurately monitor the progress of intermittent claudication patients during or after treatment. Furthermore, diagnostic tools for intermittent claudication are not always adequate to determine whether other diseases are ...
Mark Greveling   +6 more
doaj   +1 more source

Application of Oblique Lateral Interbody Fusion Combined with Bridge‐Locking Cage in Adjacent Segment Disease After Lumbar Fusion

open access: yesOrthopaedic Surgery, Volume 14, Issue 12, Page 3268-3276, December 2022., 2022
Sketch map of ROI‐A fusion cage. The self‐locking double fixation inlay designed on special PEEK fusion cage (A) was directly implanted on the axis of intervertebral space (B), firmly fixed to the upper and lower vertebral bodies through the vertebral endplate, and then locked on the fusion cage (C).
Shuai Zhang, Hui Xu, Cheng‐hui Yin
wiley   +1 more source

Oblique Lateral Endoscopic Decompression and Interbody Fusion for Severe Lumbar Spinal Stenosis: Technical Note and Preliminary Results

open access: yesOrthopaedic Surgery, Volume 14, Issue 12, Page 3400-3407, December 2022., 2022
Positions of the intervertebral retractor and the endoscopic working cannula were confirmed by intraoperative anteroposterior and lateral fluoroscopy. Objective Adequacy of decompression for oblique lateral interbody fusion (OLIF) is a real concern in patients with severe lumbar spinal stenosis (LSS).
Fei Jia   +4 more
wiley   +1 more source

Physical properties and biological effects of ceramic materials emitting infrared radiation for pain, muscular activity, and musculoskeletal conditions

open access: yesPhotodermatology, Photoimmunology &Photomedicine, Volume 39, Issue 1, Page 3-15, January 2023., 2023
Abstract Background Up to 33% of the general population worldwide suffer musculoskeletal conditions, with low back pain being the single leading cause of disability globally. Multimodal therapeutic options are available to relieve the pain associated with muscular disorders, including physical, complementary, and pharmacological therapies.
Jan Kyselovic   +5 more
wiley   +1 more source

Naftidrofuryl for intermittent claudication [PDF]

open access: yesCochrane Database of Systematic Reviews, 2008
Lifestyle changes and cardiovascular prevention measures are a primary treatment for intermittent claudication (IC). Symptomatic treatment with vasoactive agents (Anatomic Therapeutic Chemical Classification (ATC) for medicines from the World Health Organisation class CO4A) is controversial.To evaluate evidence on the efficacy and safety of oral ...
Luc M. Van Bortel   +4 more
openaire   +4 more sources

Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial

open access: yesClinical and Applied Thrombosis/Hemostasis, 2022
Background The COMPASS trial demonstrated that in patients with peripheral arterial disease, the combination of rivaroxaban and aspirin compared with aspirin reduces the risk of major adverse limb events, but it is not known whether this combination can ...
Eduardo Ramacciotti MD, PhD   +16 more
doaj   +1 more source

The Bambuí health and aging study (BHAS). Prevalence of intermittent claudication in the aged population of the community of Bambuí and its associated factors

open access: yesArquivos Brasileiros de Cardiologia, 2001
OBJECTIVE: To assess the prevalence of intermittent claudication in the aged population of Bambuí, Brazil, and to identify the factors associated with this disease.
Valéria Maria de Azeredo Passos   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy